[
  {
    "ts": "2025-12-09T10:27:00+00:00",
    "headline": "Strategic Pharma Collaborations Propel RCC Market Growth",
    "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
    "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a91df546-a5ff-36e2-878b-8d7e920eac4f",
      "content": {
        "id": "a91df546-a5ff-36e2-878b-8d7e920eac4f",
        "contentType": "STORY",
        "title": "Strategic Pharma Collaborations Propel RCC Market Growth",
        "description": "",
        "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
        "pubDate": "2025-12-09T10:27:00Z",
        "displayTime": "2025-12-09T10:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strategic-pharma-collaborations-propel-rcc-102700645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T11:55:00+00:00",
    "headline": "Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement",
    "summary": "Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. (\"Yao Pharma\"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece",
    "url": "https://finance.yahoo.com/news/fosun-pharmas-subsidiary-yao-pharma-115500092.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "2feac2e4-ea41-3769-9bf8-8b3d8686b443",
      "content": {
        "id": "2feac2e4-ea41-3769-9bf8-8b3d8686b443",
        "contentType": "STORY",
        "title": "Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement",
        "description": "",
        "summary": "Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. (\"Yao Pharma\"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece",
        "pubDate": "2025-12-09T11:55:00Z",
        "displayTime": "2025-12-09T11:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/ab9d596447b220ac4e9523a3e157a944",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rM96VtUZkIca69kjD3HKng--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/ab9d596447b220ac4e9523a3e157a944.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2S9PfH8htvNBXaNuQzh3ag--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ab9d596447b220ac4e9523a3e157a944.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fosun-pharmas-subsidiary-yao-pharma-115500092.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fosun-pharmas-subsidiary-yao-pharma-115500092.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "SFOSF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T11:30:00+00:00",
    "headline": "Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma",
    "summary": "NEW YORK, December 09, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight mana",
    "url": "https://finance.yahoo.com/news/pfizer-enters-exclusive-collaboration-license-113000303.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "27560721-10ed-3286-9723-a65bc02b14ef",
      "content": {
        "id": "27560721-10ed-3286-9723-a65bc02b14ef",
        "contentType": "STORY",
        "title": "Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma",
        "description": "",
        "summary": "NEW YORK, December 09, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight mana",
        "pubDate": "2025-12-09T11:30:00Z",
        "displayTime": "2025-12-09T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/09ea9779b53ba4a48ad58ea64e455ec5",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/29uW19vvGSMGQt7U0ERcsw--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/09ea9779b53ba4a48ad58ea64e455ec5.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3_kJYtmIghcH5VzGhidhVQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/09ea9779b53ba4a48ad58ea64e455ec5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-enters-exclusive-collaboration-license-113000303.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-enters-exclusive-collaboration-license-113000303.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]